| 摘要 |
PCT No. PCT/JP94/01641 Sec. 371 Date Mar. 29, 1996 Sec. 102(e) Date Mar. 29, 1996 PCT Filed Sep. 30, 1994 PCT Pub. No. WO95/09168 PCT Pub. Date Apr. 6, 1995Indoline compounds represented by the general formula: <IMAGE> wherein R1 represents the group <IMAGE> R2 represents a phenyl group which may be substituted or an aromatic heterocyclic group, and R3 represents hydrogen, a halogen, or a lower alkyl group, hydroxyl group, lower alkoxy group, carbamoyl group or lower alkoxycarbonyl group, and physiologically acceptable salts thereof, and their solvates, as well as 5-HT3 receptor antagonists containing them as effective components. The indoline compounds of the invention have stronger antagonism against intestinal 5-HT3 receptors than known 5-HT3 receptor antagonists and also have excellent sustained action, making them useful as prophylactic or therapeutic agents against vomiting or irritancy induced by chemotherapy or radiation, irritable bowel syndrome, diarrhea, and the like.
|
